Janus Henderson Group plc Reports New 10.3% Stake in 4D Molecular Therapeutics, Inc.

Janus Henderson Group plc (JHG) filed a Schedule 13G/A on April 7, 2026, reporting a significant increase in its stake in 4D Molecular Therapeutics, Inc. (FDMT). As of the event date on March 31, 2026, the firm beneficially owns 5,247,151 shares of common stock, representing a 10.3% ownership stake in the company. This is a substantial increase from the previously reported 0.0% position. Janus Henderson Group plc serves as the ultimate parent company for several SEC-registered investment advisers, including Janus Henderson Investors US LLC and Janus Henderson Investors UK Limited. These subsidiary asset managers exercise investment and voting discretion over managed portfolios that hold the shares. The filing indicates shared voting and dispositive power over the entire 5,247,151 share position. The acquisition was made in the ordinary course of business, without the intent to change or influence the control of the issuer. No single managed portfolio holds more than 5% of the outstanding common stock.